Dajun Yang, Ascentage Pharma CEO
Ascentage estimates $133M in proceeds as it plans Nasdaq dual listing
Ascentage Pharma’s plans for a dual listing in the US could load its coffers with about $133 million in net proceeds, the commercial drugmaker said …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
